ArticleiScience2025
Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A palmitoylation-related signature predicts prognosis and immune microenvironment features in diffuse large B-cell lymphoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a leading cause of cancer-related mortality worldwide, with drug resistance remaining a major therapeutic challenge. We integrated multi-omics data-including GWAS, eQTL, and pQTL-with Mendelian randomization to identify genes associated with breast cancer risk and therapy response. Our analyses revealed CTSF and GSTM3 as key candidates, showing consistent associations at both RNA and protein levels. Functional studies indicated that CTSF expression correlates with taxane resistance but cyclophosphamide sensitivity, while GSTM3 influences response across multiple regimens. Enrichment analyses suggest roles in immune and hormone signaling pathways. These findings highlight CTSF and GSTM3 as potential biomarkers and therapeutic targets for overcoming chemoresistance in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.